Updated
Arcus BiosciencesRCUS · Healthcare
$18.28+3.34%
Market cap$2.3B
IndustryBiotechnology
Arcus Biosciences (RCUS) Superinvestor holders
10 of the superinvestors we track hold Arcus Biosciences (RCUS) in their latest 13F filings, $158M in total.
Summary
The largest holder is Paul Marshall (Marshall Wace), with $60M, 0.1% of the portfolio.
In their latest quarter: 1 opened a new position, 3 added, 6 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Paul Marshall Marshall Wace |
Trimmed | 1,945,088 | $60M | 0.1% | Q2 2026 |
| Ken Fisher Fisher Investments |
Trimmed | 1,918,497 | $50M | 0.0% | Q3 2026 |
| Two Sigma Two Sigma Investments |
Added | 635,404 | $20M | 0.0% | Q2 2026 |
| Peter Muller PDT Partners |
Trimmed | 323,567 | $10M | 0.5% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
Trimmed | 215,613 | $7M | 0.0% | Q2 2026 |
| Man Group Man Group plc |
Added | 137,763 | $4M | 0.0% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
Trimmed | 96,417 | $3M | 0.0% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Trimmed | 83,861 | $3M | 0.0% | Q2 2026 |
| Alger Fred Alger Management |
New position | 60,494 | $2M | 0.0% | Q2 2026 |
| Acadian Acadian Asset Management |
Added | 15,189 | $390,000 | 0.0% | Q3 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 10 |
| Q1 2026 | 12 |
| Q4 2025 | 10 |
| Q3 2025 | 11 |
| Q2 2025 | 9 |
| Q1 2025 | 12 |
| Q4 2024 | 9 |
| Q3 2024 | 10 |
Questions about Arcus Biosciences
Which superinvestors own Arcus Biosciences?
10 of the superinvestors we track hold Arcus Biosciences (RCUS) in their latest 13F filings, $158M in total. Paul Marshall, Ken Fisher, Two Sigma, Peter Muller, Ensign Peak, Man Group.
Who is the largest superinvestor holder of RCUS?
The largest holder is Paul Marshall (Marshall Wace), with $60M, 0.1% of the portfolio.
From Arcus Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.